CD8A and neoplasm: In our experiments, the decline in the number of Tregs, the increase in the ratio of CD8+ T cells to FoxP3+ CD25+ CD4+ Tregs and the lymphopenic environment after cyclophosphamide treatment favor enhanced priming of tumor-specific immune responses during vaccination.